<DOC>
	<DOCNO>NCT02776215</DOCNO>
	<brief_summary>Open-label Study Investigate Pharmacokinetics Safety Tasimelteon Children Adolescents .</brief_summary>
	<brief_title>Study Pharmacokinetics Safety Tasimelteon Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Smith-Magenis Syndrome</mesh_term>
	<mesh_term>Sleep Disorders , Circadian Rhythm</mesh_term>
	<criteria>1 . Males females legally blind [ define visual acuity 20/200 less betterseeing eye best conventional correction ( glass contact lens ) and/or visual field 20 degree less betterseeing eye ] , 3 &lt; 18 year age males female SMS 3 &lt; 16 year age nighttime sleep complaint 3 &lt; 18 year age males female ASD 3 &lt; 18 year age nighttime sleep complaint ; 2 . Weigh least 16 kg ; 3 Diagnosis SMS determine prior positive genetic test result indicate parent/guardian ; Diagnosis ASD indicate parent/guardian ; diagnosis Non24 determine DSM5 diagnostic criterion Circadian rhythm sleepwake disorder , Non24hour sleepwake hour type : 1 . A persistent recurrent pattern sleep disruption primarily due alteration circadian system misalignment endogenous circadian rhythm sleepwake schedule require individual 's physical environment social professional schedule ; 2 . The sleep disruption lead excessive sleepiness insomnia , ; 3 . The sleep disturbance cause clinically significant distress impairment social , occupational , important area function . 1 . For blind subject : Subjects probable diagnosis current sleep disorder Non24Hour SleepWake Disorder primary cause sleep disturbance base clinical investigator medical judgment ; 2 . For blind subject : History ( within 12 month prior screen ) psychiatric disorder include ADHD , Neurodisabilities , Major Depressive Disorder , Generalized Anxiety Disorder , Axis II Disorders , delirium psychiatric disorder , successfully treat resolve opinion clinical investigator would affect participation study full compliance study procedure ; 3 . History intolerance and/or hypersensitivity melatonin melatonin agonist ;</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>